{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T06:27:17Z","timestamp":1767421637800,"version":"build-2065373602"},"reference-count":20,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2006,7,4]],"date-time":"2006-07-04T00:00:00Z","timestamp":1151971200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2006,8]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>To evaluate the effects of MN\u2010001, a novel orally active anti\u2010inflammatory agent, in suppressing the bladder hyperactivity resulting from ovalbumin (OA)\u2010induced mast\u2010cell stimulation in a rat model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MATERIALS AND METHODS<\/jats:title>\n                    <jats:p>Sprague\u2010Dawley rats of both sexes were divided into five groups of 10 each, with group 1 as the control and groups 2\u20135 undergoing OA sensitization to produce mast\u2010cell degranulation using an established method. At 14\u2003days after sensitization, rats were given an acute intravesical challenge: in group 1, by saline (control), and in groups 2\u20135, with \u2248\u200a2\u2003mL of OA (10\u2003mg\/mL in sterile saline). Groups 3\u20135 received the investigational agent MN\u2010001 orally at 10, 30 or 50\u2003mg\/kg, respectively, 1\u2003h before intravesical OA challenge. Urodynamics were then evaluated to quantify the frequency of contractions (voids), intercontractile interval (ICI) and non\u2010voiding contractions (NVCs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      Acute intravesical OA challenge in rats in group 2 caused contractions of bladder smooth muscle, leading to a significant (\n                      <jats:italic>P<\/jats:italic>\n                      \u2003&lt;\u20030.05) dose\u2010dependent increase in NVCs and a decrease in ICI. Rats pre\u2010treated with MN\u2010001 at 30 and 50\u2003mg\/kg (groups 4 and 5) had significantly fewer NVCs and a greater ICI than rats in group 2 (\n                      <jats:italic>P<\/jats:italic>\n                      \u2003&lt;\u20030.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>OA challenge in OA\u2010sensitized rats produces bladder hyperactivity, as reflected in significantly more NVCs and a lower ICI. At doses of 30 and 50\u2003mg\/kg orally, MN\u2010001 produces significant protection against the OA\u2010induced bladder hyperactivity. MN\u2010001 might have a role in managing mast cell activity and the associated bladder symptoms in patients with interstitial cystitis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1464-410x.2006.06274.x","type":"journal-article","created":{"date-parts":[[2006,7,6]],"date-time":"2006-07-06T21:41:38Z","timestamp":1152222098000},"page":"430-434","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["MN\u2010001, a novel oral anti\u2010inflammatory agent, suppresses bladder hyperactivity in a rat model"],"prefix":"10.1111","volume":"98","author":[{"given":"MAHADEVAN","family":"RAJASEKARAN","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KENNETH W.","family":"LOCKE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. LOWELL","family":"PARSONS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,7,4]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(03)00774-X"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(01)01129-3"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)66981-9"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000083020.06212.3d"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0701793"},{"key":"e_1_2_7_7_2","doi-asserted-by":"crossref","unstructured":"LockeK.Phase I study of MN\u2010001 an oral anti\u2010inflammatory agent for the treatment of asthma. Presentation number 603 American Academy of Allergy Asthma and Immunology 61st Annual Meeting March 1822 2005San Antonio TX USA","DOI":"10.1016\/j.jaci.2004.12.616"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(02)02280-X"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/nau.20122"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199301283280408"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.22.8972"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/339064a0"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198707023170106"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.1982.tb06976.x"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)42981-8"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02007746"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.1995.tb07840.x"},{"key":"e_1_2_7_18_2","first-page":"88","article-title":"Experimental model for the study of bladder mast cell degranulation and smooth muscle contraction","volume":"9","author":"Saban R","year":"1991","journal-title":"Semin Urol"},{"key":"e_1_2_7_19_2","doi-asserted-by":"crossref","first-page":"682","DOI":"10.2460\/javma.1999.215.05.682","article-title":"Feline interstitial cystitis","volume":"215","author":"Buffington CA","year":"1999","journal-title":"J Am Vet Med Assoc"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)39722-7"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410X.1997.00415.x"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1464-410X.2006.06274.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1464-410X.2006.06274.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T17:23:57Z","timestamp":1761758637000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/j.1464-410X.2006.06274.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7,4]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["10.1111\/j.1464-410X.2006.06274.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1464-410x.2006.06274.x","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"type":"print","value":"1464-4096"},{"type":"electronic","value":"1464-410X"}],"subject":[],"published":{"date-parts":[[2006,7,4]]},"assertion":[{"value":"2006-07-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}